Until recently, sickle cell disease (SCD)—the most common inherited blood disorder in the United States—was primarily considered a pediatric disease, with most children not surviving into adulthood. That’s changed over the last two decades, thanks to innovative advancements in care and treatment. But even as these advancements have helped more children reach adulthood, health systems and providers have struggled to help children transition to adult care, resulting in high rates of complications and mortality for young adults.